Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilzemetkib in Chinese Patients With NF1 and MPNST
NCT05011019Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vilzemetkib in neurofibromatosis type 1 (NF1), malignant peripheral nerve sheath tumor (MPNST), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2021; status: terminated.
02
Drugs
vilzemetkib
03
Conditions
neurofibromatosis type 1 (NF1)malignant peripheral nerve sheath tumor (MPNST)
Beyond the preview
Go deeper on NCT05011019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05011019.